Regeneron Pharmaceuticals Inc (REGN)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 3,990,700 | 3,973,400 | 3,904,900 | 3,851,800 | 4,047,100 | 4,221,000 | 4,333,700 | 4,427,100 | 4,738,900 | 6,231,800 | 6,855,300 | 9,092,600 | 8,946,800 | 7,474,100 | 6,680,000 | 3,989,200 | 3,576,600 | 3,085,300 | 2,770,700 | 2,429,900 |
| Total assets | US$ in thousands | 37,759,400 | 37,441,900 | 36,086,800 | 34,369,600 | 33,080,200 | 32,163,300 | 30,657,500 | 30,059,900 | 29,214,500 | 27,677,800 | 27,205,800 | 26,348,700 | 25,434,800 | 23,671,500 | 21,485,900 | 17,772,200 | 17,163,300 | 16,084,000 | 14,428,700 | 15,757,500 |
| Operating ROA | 10.57% | 10.61% | 10.82% | 11.21% | 12.23% | 13.12% | 14.14% | 14.73% | 16.22% | 22.52% | 25.20% | 34.51% | 35.18% | 31.57% | 31.09% | 22.45% | 20.84% | 19.18% | 19.20% | 15.42% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $3,990,700K ÷ $37,759,400K
= 10.57%
Regeneron Pharmaceuticals Inc's operating return on assets (operating ROA) has shown a generally positive trend over the past few years, indicating efficient utilization of its assets to generate operating income.
The operating ROA started at 15.42% as of March 31, 2020, and steadily increased to reach a peak of 35.18% by December 31, 2021. This significant increase over the period demonstrates the company's ability to generate higher operating income relative to its assets deployed.
However, the operating ROA fluctuated in the subsequent quarters, with a slight decrease to 25.20% by June 30, 2022, followed by a further decline to 10.57% by December 31, 2024. These fluctuations suggest potential challenges in maintaining the same level of operating efficiency seen in previous years.
It is important for Regeneron Pharmaceuticals Inc to closely monitor and analyze the factors contributing to these fluctuations in operating ROA to ensure sustainable profitability and efficient asset utilization in the future.
Peer comparison
Dec 31, 2024